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Abstract 
Functional food (FF) is a relatively new sector in the food industry. FF are products that have an added 
nutritional value for consumers that is communicated through nutritional and health claims, and act as 
preventive agents of chronic diseases. Innovation of new FF products has grown to become an important 
impact in research towards preventing welfare diseases. The rate of innovation in this field is 
nevertheless low and the willingness of companies to invest in ideas and research projects that will lead 
to novel FF products is today weak. The main reason is the regulations for health claims. 
 
The purpose of this study is to investigate the venture creation process of FF based start-ups, with a case 
specific research question of how an analysis technique targeting the food industry can be 
commercialized. The purpose will be addressed by simultaneously investigating different venture 
creation activities, and how these activities can be applied for FF.  
 
In order to build a theoretical framework for the analysis, an extensive literature search connected to the 
key terms yielded four categories of venture creation activities:  
• Planning activities  
• Establishing legitimacy 
• Market activities  
• Resource transformation  
These categories were connected to four important aspects specific for FF:  
• Regulatory approvals  
• Product development 
• Intellectual property rights  
• Consumer acceptance  
 
The methodology used to explore this area and get a deeper insight in the research topic was by 
conducting qualitative insider action research of one case. The data has been collected through; 
numerous meetings with founders and stakeholders, daily operation actions, observations, notes, 
experiences, conversations, memories and joint-actions from one year of venture creation in the case. 
 
The empirical data collection revealed that the studied venture chose to perform an iterative 
conceptualization process followed by a business model canvas and a timeline of activities in the 
category of planning activities. The venture met issues when investigating regulatory approvals in the 
category of establishing legitimacy. Through contact with experts they revealed a path that potentially 
would not include the health claim regulation. The market activities were primarily focused on customer 
development where identifying customer demand was considered of major importance. The 
product/technology development as well as funding applications was left to be performed after the 
concept was verified by customer demands.  
 
The conclusion consists of a proposed framework of how to commercialize an analysis technique 
targeting the FF sector. This proposed framework could potentially serve as a general framework when 
commercializing other FF products or services. 
 
Key terms: Functional food, glycaemic response, venture creation, start-up, business development, 
commercialization, analysis technique 
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1. Introduction 
This master’s thesis is based on a case study investigation of a start-up venture, stemming from 
scientific research at Lund University, called ViscoSens. ViscoSens aim to operate in the food industry 
with a novel functional food (FF) concept that appeared as a result from one of the founder’s research. 
The research results leading to the concept include an analytical measurement of the glycaemic 
response, also known as blood sugar level, after consumption of food products. The analysis is 
performed outside the body (in vitro) and correlated with data from meal studies in healthy humans (in 
vivo). The aim of the thesis work is to approach the business development of the start-up venture from 
four strategic areas of venture creation: planning activities, establishing legitimacy, market activities and 
resource transformation with purpose to create a feasible FF business case. The investigation areas will 
be split into smaller segments on which the theoretical framework will be based to provide a solid base 
for analysis. These segments are: regulatory approvals, product development, intellectual property rights 
(IPR) and consumer acceptance. A schematic overview of the investigation topics and how they are 
connected is shown in figure 1 below.  
 
 
 
 
 
1.1 Background 
1.1.1 Venture creation process 
The venture creation process is when a new organisation is formed and how it develops to a revenue 
generating company. The most relevant activities linked to the venture creation process could be 
summarized into different categories: Planning activities, Establishing legitimacy, Market activities and 
Resource transformation. The categories are linked together according to figure 1 above and will be 
further analysed both theoretically and empirically in the case study below. The lack of research on the 
creation process of start-up ventures operating in the FF sector led to this thesis since most previous 
research approaches FF businesses from the perspective of larger corporations such as Nestlé and 
Kellogg’s (Williams Middleton, 2010). 
Figure 1: Overview of the thesis topics based on (Liao and Welsh, 2008). 
Planning activities 
Establishing 
legitimacy Market activities 
Resource 
transformation 
Regulatory approvals Consumer acceptance IPR Product development 
FF business case 
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1.1.2 Traditional and modern innovation processes 
In traditional entrepreneurship literature, the innovation process is described as a linear process from the 
discovery of an invention/research results to the transformation into an innovation where money is 
generated from the invention. This linear process viewed in figure 2 below is referred to as a technology 
push market strategy (Rothwell, 1992), (Brem & Voigt, 2009). This innovation process is widely used 
for classical university based inventions such as pharmaceuticals and materials, which characterizes that 
operational systems are created around the invention such as the company formation, sales force 
establishments and R&D operations, followed by the creation process of a new product. What usually 
lack in this strategy are customer/consumer interactions and a search for their needs and demands.  
Modern innovation processes are built on the principle that was missing in technology push strategies, 
customer/consumer demand. These strategies are called market pull and customer development 
strategies (Blank, 2012). The principle that characterizes these strategies are that the customers are the 
most central piece of a business and therefore, they should be a part of the product creation. Moreover, 
the process is iterative through constant trial and error phases (figure 3). There, the product demand 
should be revealed and validated before the product is created and the company is formed. 
1.1.3 Introduction to FF 
During the second part of the 20:th century the socioeconomic development, in countries such as in 
Western Europe, improved steadily which led to safe food supply and increased human life expectancy. 
Furthermore, as the steady supply of food and the growth of the welfare society solved famine1 in the 
western countries, it also created an increase in chronic diseases such as cardiovascular diseases, 
diabetes type-2 and obesity connected to dietary factors and poor lifestyle. The main underlying aspects 
for chronic diseases are over-consumption of food and malnutrition (Verhagen et al., 2010). However, 
proper nutritional diets are a main factor to improve the societal health status, which implies that a 
general improvement of public health will come from changes in dietary behaviour rather than an 
increase of medical treatments (Verhagen et al., 2010). During the recent years, the interest of new food 
products with positive health impact on consumers has steadily increased (Malla et al., 2014). 
 
No general accepted definition of FF exists but scientists define it as foods that have an added 
nutritional value for consumers, communicated through nutritional and health claims (Schaafsma & 
Kok, 2005). This is also the definition of FF used in this thesis. General principles of FF are that:  
• There should not be any side effect due to normal use. 
• No disturbance of a healthy eating behaviour  . 
                                                
1 Famine is referred to a scarcity of food in the society 
Company buildingCustomer creationCustomer validationCustomer identification
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P
Figure 2: Technology push strategy (Rothwell, 1992). 
Company buildingCustomer creationCustomer validationCustomer identification
Pivot
ST
O
P
ST
O
P
ST
O
P
N w technology Operation  and systems N ew product/service N ed?
ST
O
P
Figure 3: Customer development strategy according to Blank (2012). 
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• Scientifically proven and substantiated health claims.  
Furthermore, FFs are considered as a part of a balanced diet (Schaafsma & Kok, 2005). FFs are of today 
considered as a sustainable trend driven by market forces such as the expanded knowledge in the 
relationship between nutrition and health, the increased occurrence of chronic diseases and a larger 
buying power of consumers (Schaafsma and Kok, 2005). 
1.1.4 Current environment for FF concepts 
Today, innovation is viewed as vital for the success and a source of economic growth in the modern 
society (Hårsmar et al., 2014). However, the rate of innovation in the food industry is although low and 
the willingness for companies to invest in ideas and research projects that will lead to novel FF concepts 
is today weak. Some essential factors influencing the low occurrence of food innovations are the risks 
with regulatory approvals, low return on investments and the problem with consumer communication 
through labelling and marketing (Malla et al., 2014). The communication of health benefits to 
consumers is the key for the ability to create added value in a FF product. The communication link is 
through health claims that include labelling and marketing communication. Development of credible 
and communicable health claims can produce benefits for the society in form of improved public health 
and reduced costs connected to health care (Malla et al., 2014). A new regulation policy has been 
established in the European Union (EU) from 2007 with an aim to standardize the procedure of granting 
health claims in all membership countries at the same time. Furthermore, an additional aim of the 
regulation is to give safe and correct recommendations of appropriate food products to consumers 
(Regulation EC No. 1924/2006, 2007). 
 
For companies, the aspects of regulatory approvals affects their path of commercializing new 
innovations in the food industry, both regarding investments into research, product development and 
IPR management. Baylor (2014) argues the necessity for food industry companies in an early project 
stage to adapt the regulatory framework to the product development process. This has not been the case 
historically. The product development require significant amount of research invested in a project. This 
includes identification of functional compounds and assessing their physiological effect in addition to 
clinical trials on product efficiency. These are necessary procedures to gain credibility and basic data for 
the approval process of health claims. If the regulatory requirements remain unidentified through the 
product and conceptual development, the costs of performing pivots could eventually lead to market 
failures (Siró et al., 2008). 
 
Initiation of a FF project is a matter of risk. A project needs financial investments to be executed. IPR 
are generally viewed as an asset that reduces the risk when making an investment decision. The food 
industry has, however, not fully adopted the possibility to protect investments in research through 
patents. Instead companies are keeping trade secret as the general mean for protection (Malla et al., 
2014). Chong et al. (2008) argues that an investment in IPR such as patents has a low rate of success in 
the food industry due to the low margins that the producers can obtain and therefore low return on 
investments. The reason behind a constant price pressure is the relative easiness for copycats to mimic 
an invention. This factor is an obstacle for R&D based food companies when trying to attract both 
external and internal capital to be able to grow and develop projects into commercial products (Hårsmar 
et al., 2014). 
 
To understand the consumer and to analyse their acceptance are major factors to consider for the vitality 
early on in a development process. According to the strategic triangle presented by Schaafsma and Kook 
(2008) a FF can only be vital if the consumer acceptance is satisfied. That implicates four factors: the 
taste, understanding of the concept, emotional fit and reliability of the documented efficiency. If these 
factors are accomplished the rate of success will increase. 
 
These topics are critical aspects for start-up ventures when entering the FF sector and they are of certain 
relevance when creating related strategies, leading to a proposal of a FF business case. This qualifies 
them to be investigated in this thesis work. 
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1.1.5 Case study: ViscoSens 
The data collection will be performed in collaboration with a start-up venture from Lund University 
called ViscoSens. ViscoSens has been of certain interest for the author already since the venture was 
formed both since the areas of food technology and nutrition are of personal interest for the author and a 
personal family relationship to one of the founders. Therefore, the author has followed ViscoSens during 
the operational years and sized the opportunity to work with ViscoSens when this thesis was accepted. 
The scope of the thesis has been under constant change during the process. Firstly, the author started 
working with theories around product development of the analysis technique. After a while, the author 
thought that the product development aspects contained much sensitive information that could lead to a 
patent application. Then the thesis seemed too shallow when the most essential parts was removed. 
Therefore the author decided to change scope to a business development perspective since the author 
has educational background within entrepreneurship and business design from Chalmers University of 
Technology in Gothenburg. Also within business development have the scope been changed and been 
narrowed to the venture creation process of FF businesses. 
1.2 Purpose 
The purpose of this thesis work is to investigate how a transformation of research results from university 
into a FF venture could be performed. 
 
Today, little is known of how researchers within FF can work as entrepreneurs and commercialize their 
inventions in an optimal way. Conclusions from this thesis work have potential to contribute to new 
knowledge and insights in the area of food technology, nutrition and entrepreneurship. The reader will 
be guided through a case study of a start-up venture from Lund University, called ViscoSens, on their 
way to transform research results into a business case. The research question can be summarized as 
followed. 
 
How can an analysis technique targeting the food industry be commercialized in the creation of a FF 
venture? 
1.3 Aims 
The aims of this thesis work could be summarized into four bullet points: 
• Creation of a theoretical framework that gives the reader insight into general topics regarding FF 
and venture creation. The theoretical framework will form a suitable base for strategies of how to 
create a FF business case. 
• Empirically collect data from the venture in the case study as a complement to theory to create 
an analytical framework  
• Make analyses of the findings to propose a way to construct a FF business case. 
• Make recommendations of further work towards commercialization based on the conclusions. 
1.4 Delimitations 
This thesis work will focus on specific research from a start-up venture in Lund operating initially on 
the Swedish market. The scope of this thesis work will be delimited to development related aspects in 
the FF sector of the food industry. Other aspects regarding start-up ventures as well as other industries 
sectors and markets are left out of the study.  
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2. Theoretical framework 
The theoretical framework is built on the available theory and information regarding venture creation 
processes and FF. This is served as a base for the empirical study. The theoretical framework and the 
empirical study are jointly creating the analytical framework that the analysis in chapter 5 will be based 
upon. The theoretical framework starts with theories around venture creation processes followed by FF 
specific categories. The categories are: regulatory approvals of health claims, product development, IPR 
and consumer acceptance.  
2.1 Venture creation process 
The venture creation process could be referred to the process where a new organisation is formed and 
how it develops into a revenue generating company. However, few studies have of today explored the 
venture creation process empirically and none of the studies are related to the area of FF. Therefore, a 
general approach of the venture creation process will be anchored in this theoretical framework. An 
illustration of the definition of a venture creation process used in this thesis could be viewed in figure 4 
below.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The venture creation process is characterized of different events or start-up activities during the 
gestation time. The latter refers to the time elapsed from the first to the last start-up activity. The process 
could vary a lot between different start-ups due to that they have to make intentional choices for 
maximum utilization of limited resources and therefore, a venture cannot perform every desired activity 
(Liao and Welsh, 2008). Gartner (1985) argues that a new venture is created through series of actions 
taken by the entrepreneurs. Such events are; developing prototypes, seeking funding, hiring employees 
and conducting market research. These events take place at different times, to different degrees and in 
different order dependent on the kind of start-up such as if it is a technology based or non-technology 
based venture. Liao and Welsh (2008) have identified that there are four different characteristics that 
dictate how start-up activities evolve. Firstly, not all activities are needed for start-ups, like if money is 
secured there is no need to seek financial support. Secondly, entrepreneurs need to prioritize since they 
have limited cognitive abilities and are not able to do all possible activities simultaneously. Therefore, a 
high degree of variation will occur between certain orders of activities between different start-ups. 
Thirdly, different activities depend on each other and the ability to start one activity depends on the 
completion of another. An example could be that a contract with a large customer would enable 
possibilities of capital injection for the venture. Fourthly, some activities are more important in an early 
Venture creation process 
 
Transition 1: 
Identify idea 
Transition 2: 
Incorporate 
RESEARCH NEW FIRM 
Actions towards creation 
of a new venture 
Gestation/incubation 
Actions for 
growth and 
sustainability 
Early-stage 
research and 
development 
Figure 4: Model for the venture creation process (Williams Middleton, 2010). 
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stage and some in a later stage, therefore the activity importance depends on the stage of venture 
development. From this argumentation, it is expected that start-up entrepreneurs engage in different 
patterns of activities during the gestation process (Williams Middleton, 2010). 
 
The argumentation of the non-linear pattern of the venture creation process made Liao and Welsh 
(2008) distinguish two major categories of activities; planning activities and operational activities. 
Planning activities refers to events that coordinate activities at the early stage of venture creation. Such 
events could be conceptualization, value proposition generation, creation of a business model and 
market entry strategies (Williams Middleton, 2010). Here it is of necessity by the entrepreneur of a 
venture to recognize opportunities and keep ability to adapt to external environmental factors when it 
changes. This is especially apparent for ventures competing in a technology-based industry. 
Consequently, when planning for entrepreneurial activities, they should focus on continuously assessing 
technology advantages and identifying market opportunities (Liao and Welsh, 2008).  
  
Operational activities refer to events occurring after the planning phase and can be divided into three 
subcategories: legitimacy building activities, market related activities and resource transformation 
activities (Liao and Welsh, 2008). Legitimacy establishing can be related to activities that define a 
physical and legal boundaries, such as receiving a regulatory approval for a physical product before 
market launch, which in turn generate legitimacy for the venture (Williams Middleton, 2010). Building 
legitimacy lays the core foundation of a venture and enables access to critical resources such as specific 
target groups, as well as, building trust towards investors. Market activities are such that can be related 
to customer relationship activities, customer development, sales and promotions (Williams Middleton, 
2010). These activities are considered as important when dealing with technology products due to the 
intense financial requirements during its development. Therefore, activities exploring market demands 
are often intense and resource demanding during an early stage of the venture creation process. 
Resource transformation is the generation of assets that acquire and combine human, financial and 
technological resources, such as product development and IPR (Williams Middleton, 2010). Ventures 
need to develop an initial resource base to survive in a dynamic high competitive technology industry 
where tangible and intangible resources are needed, especially when dealing with venture capitalists. 
This is considered as necessary assets to develop or acquire but it is also time consuming and could slow 
the time to market substantially (Liao and Welsh, 2008). Table 1 below shows the categorization of the 
venture creation activities. 
 
Table 1: Categorization of the venture creation process (Williams Middleton, 2010). 
Venture creation categories Venture creation activities 
Planning activities Conceptualization, searching for market opportunities, business model, 
creation of strategies 
Establishing legitimacy Regulatory affairs, determine legal form of venture 
Market activities Customer development, verification of business model and concept, 
secure suppliers and distributors 
Resource transformation Product development, IPR, secure funding sources 
 
2.1.1 Priority of activities 
This study will investigate the venture creation categories that seem most potential to prioritize in early-
stage FF businesses. The category of planning activities will scope the conceptualization process of how 
the concept is formed in addition to how the value proposition is formed through a tool called business 
model. The conceptualization usually starts with the “bird-in-hand” principle according to effectuation 
logic created by Read et al. (2010). The bird-in-hand principle means that the entrepreneurs start with 
their means by answering three questions: Who I am, what I know and whom I know. This generated 
possibilities to create a concept that originated from the identified means. The business model is a tool 
that describes, in a general approach, how the business will be executed and it will set the framework for 
the concept. The process of business modelling is individual for every start-up venture and could be 
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performed in many different ways. The most common way of creating a business model is through a 
framework called business model canvas, created by (Osterwalder, 2004). The theory behind business 
model canvases is broad and mostly target general technology based ventures. Hence, the theory is not 
specifically targeting FF businesses and therefore it will not be further described in the theoretical 
framework, instead the author recommends reading more about business model canvas theory in the 
doctoral thesis by Osterwalder (2004). The operational activity of establishing legitimacy will be 
through the theory of regulatory approvals. This is of major importance in a FF venture since the 
regulations will set the boundaries of the concept. Regarding resource transformation, both product 
development and IPR are prioritized due to the importance when establishing assets in a venture, which 
often is specific for different industries and sectors. The market activities are dependent on consumer 
acceptance and therefore, they will be further theoretically described by consumer acceptance theory of 
FF products.  
2.2 Functional Foods 
Two consultancy firms performed a worldwide strategic survey in the food industry in 2002. The study 
indicated that 90 % of top managers in food production companies and retail stores expected a strong 
and expansive progression of the health connected food products. This meant that the integration of 
health and foods was expected to have a strong impact on food innovations. This trend was a seed for 
the standardized term in the food industry, today known as FF (Schaafsma & Kok, 2005).  
2.2.1 Regulatory approval 
This study will investigate the most common regulatory classification of FF, called food with health 
claims. The theoretical contribution to this classification will consist of definitions and background 
information to the regulation. The chapter of regulatory approval ends with a summarizing table of the 
classification.  
2.2.1.1 Health claims  
When the concept of FF was created, most of the European countries viewed it as products that would 
fall under jurisdiction of each individual nation in Europe. However, some countries such as Germany 
and Denmark viewed FF as pharmaceuticals, which was possible meanwhile it was a decision for each 
country. The consequence of individual national perceptions of FF was that free trade could not be 
established within the EU. In 2006, the EU introduced a new regulation regarding health claims (EC No. 
1924/2006, 2007) with a purpose to harmonize the legislation of FF and establish free trade. The filing 
for health claims was decided to go through a central organisation administered by the European 
Commission (EC), called European Food and Safety Authority (EFSA), and be approved after opinion 
from each EU member country. The regulatory process for health claims could be seen in figure 3. 
 
 
Presently, two generations of FF exist on the market. The first generation is foods with enhanced 
nutritional values and is frequently connected with nutritional claims. Nutritional claims primarily gives 
the consumer information about the nutrients present in a product and their physiological significance. 
An example of a nutritional claim could be “this product is rich in vitamin D, which helps to strengthen 
your bones” (EC No. 1924/2006, 2007). This first generation of FF presently makes a substantial 
contribution to the total market of FFs. This mainly due to the non-requirement of extensive nutrition 
research in the process of substantiating a claim since these claims are based on publically known 
knowledge from many years back in time. This gives opportunities for food industry companies to, in a 
relatively cheap way, participate in the FF market.  
Health 
Claim 
proposal 
Dossier 
submission of 
scientific data 
collection 
EFSA Opinion EC Approval/ rejection 
Figure 5: Regulatory process of health claims. 
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The second generation of FF is foods with substantiated health claims and physiological benefits. The 
claims can be differentiated into “reduced disease risk” claims and “enhanced function” claims, 
dependent on the kind of beneficial effect (EC No. 1924/2006, 2007). A typical example of a second-
generation FF is betaglucans, a dietary fibre from oats or barley that has proven health benefits of lower 
cholesterol levels and lower blood sugar levels (glycaemic response) after consumption. To obtain these 
claims, it is necessary to extract and purify the betaglucans from the cereal kernels since the fibre level 
is not originally high enough. The general characteristics of second generation FF are that they have 
basis in knowledge of health and nutrition and that they claim benefits that exceed the benefits of other 
traditional foods. This concept triggers the food industry to create new innovative food with added 
values based on research (Schaafsma & Kok, 2005). 
 
The basic rules to make health claim implies that (Schaafsma & Kok, 2005): 
• Consumers have the basic right to be informed of the full characteristics of the foods they are 
consuming. 
• Claims should not mislead consumers. 
• Medical claims are not allowed for foods. 
• Claims should not interfere with the general guidelines accepted for a healthy diet. 
 
The basic information that needs to be collected to obtain an approved health claim is sufficient 
scientific evidence of the claimed health benefits. The breakthrough of this regulation, except the free 
trade establishment, was that reduced disease risk claims prior was considered as medicinal claims, 
which now became allowed if approved (Siró et al., 2008). During 2010, a new paragraph was 
introduced to the EC No. 1924/2006 (2007) with a prepared list of allowed health claims, named under a 
specific paragraph known as §13.1. All stakeholders who wanted to claim health benefits of their 
products had to file a dossier with scientific argumentation and evidence why their specific substance 
should receive a health claim. The approved claims were only including specific characterized 
ingredients on a molecular level that had sufficient scientific studies with clear cause-effect evidence. 
The cause-effect evidence means that a certain amount of ingredient lead to a measurable response 
effect of claimed health benefits. A small percentage of the applications were approved, which created a 
debate because many companies lost their business (Siró et al., 2008). Furthermore, if the health claim 
was approved, they were free to use for everyone i.e. a stakeholder had to invest in research and 
development, which external stakeholders could benefit from as well. Nevertheless, when organisations 
file for new health claims it is most likely based on novel research and therefore the application should 
be filed according to §13.5 in the EC directive (EC No. 1924/2006, 2007). If the claim is granted as a 
§13.5 claim, the organisation will be granted a sole property protection of the claim for five years.  
 
However, the present European legislation does not consider FF as a category of food products, rather 
like concepts (Siró et al., 2008). Therefore, the numbers of rules to be applied are numerous and highly 
dependent on the natural origin of the food as well as the physiological effects, creating problems for 
existing companies trying to receive health claim approvals of their products.  
 
A table defining the regulatory approval route of health claims can be viewed below (table 2).  
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Table 2: Regulatory approval of health claims (EC No. 1924/2006, 2007). 
 Regulatory approvals of health claims 
General criteria Substantiated with generally accepted scientific data, non-misleading & approved 
by all EU member states. 
Approving authority The EC by opinion from EFSA and all member states in EU. 
General critique The amount of scientific evidence and labelling rules is too complex and hard so 
the ability to fulfil all these is very costly. Limited competitive advantage 
regarding property of claims could be generated. Long time to market. 
General procedure Construct and send in a dossier with substantiated scientific evidence of health 
benefits to national authority agency, which distributes it further to EFSA. 
Dossier should contain material of substance characterisation and cause-effect 
evidence. Scientific opinion from EFSA within 5 months, decision by the EC 
based on the opinion provided. 
Costly procedures Legal consultant services. Scientific studies and correspondence with approving 
organisation. Delayed time to market. 
Time consuming 
procedures 
Creating the dossier with scientific substantiated data. Recommended 
frameworks are provided by EFSA in Journal 2012;10 (3):2604. Administration 
procedure by the authorities.  
Impact on company Long time to approval and market entry. Costly process of receiving an approval. 
Approved health claim is universal for everyone to use after five years of health 
claim property of the filing organization. 
2.2.2 Product development of FF 
The development and commercialization of FF is a complex, risky and expensive process (Siró et al., 
2008). Some main factors that need to be taken into consideration before initiating the product 
development process are technological obstacles, legislative aspects, IPR for investment purposes and 
consumer demands.  
 
The current product development and commercialization strategies of FF primarily focus on: the 
conceptualization of the innovation process, identification of market opportunities and how the 
regulatory environment affects FF innovations (Herath et al., 2008). Menrad (2003) concluded that the 
total cost of developing a new conventional food product is around US$ 1-2 million and indicated that 
the development of FF products would exceed this number by far. Furthermore, these costs could be 
explained by the demand of resources and knowhow in nutritional and food technology research, in 
addition to knowledge in the medical field to be able to prove the efficiency of the claims. Moreover, a 
commercial actor needs to present and fulfil the requirement of strict scientific evidence and verification 
of efficacy, including statistically validated data from model systems in intervention studies. Menrad 
(2003) argues that this complex and investment requiring process inhibits industry actors to enter the 
market segment of FF.  
 
Multinational food companies are companies that possess necessary resources for product development 
and marketing as well as well-known brands. Therefore, they should be the ones to invest in this market 
according to Siró et al. (2008). These companies also gain opportunities to differentiate and create 
competitive advantages if developing products in this segment. Pharmaceutical actors are also interested 
in the FF sector due to the shorter development time and lower product development costs compared to 
pharmaceutical products. Furthermore, they also possess an established experience in clinical trials to 
substantiate health claims (Siró et al., 2008).  
 
There are a limited number of small and medium sized food companies (SMEs) acting on FF market. 
Menrad (2003) argues that SME companies mostly produce niched products following pioneering 
products of multinational companies. Furthermore, Menrad (2003) argues that these products only 
survive a short time on the market. The reason behind this should be that SMEs lack knowhow and 
financial resources for intensive R&D, marketing activities and regulatory approvals. 
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2.2.3 Intellectual property rights  
Unlike the general biotechnology industry, IPR does not appear to have a positive impact on innovation 
in the FF sector. Herath et al. (2008) argues that patents have a significant negative impact on the 
number of FF product lines introduced on the market. Moreover, they argue that acquiring IPR from 
other companies also have a negative impact on the number of product lines in development.  
 
There are some underlying reasons why certain FF projects do not turn out into launched products. One 
of those is the technology spillover effect. Technology spillover is a type of externality that is created 
when an innovative and R&D based company invests in research stemming into a new technology that 
eventually will contribute to a reduction in costs for development of a similar product for competitive 
companies. This state creates room for companies to “free-ride” on innovative firms and that eventually 
creates lack of incentives to invest in such research. According to Malla (2014), the technology spillover 
effect is created because FF based companies internationally uses trade secrets extensively instead of 
patent protection to protect their investment. 
 
Another cause of the spillover effect described by Chong et al. (2008) is that the greater the market 
impact of a successful invention, the greater the threat of “copycat” companies bringing competitive 
products to the market. Aligned with this is the aspect of investments in approved health claims, as 
described in the health claim section above, that will only generate a five year property protection. 
Another aspect is that food patents most often exist of substance extraction methods from known food 
products. These methods are usually relatively easy to reverse engineer with slight difference but with 
same outcomes, which will not infringe on a patent. Furthermore, this gives the opportunity for copycats 
to produce a product with lower raw material costs and higher profit margins and therefore, they can 
offer the product to lower prices (Chong et al., 2008). It has been proposed that this phenomenon is 
playing a significant role in the relatively low rate of innovations in the FF sector. To counteract these 
circumstances an industry actor needs to emphasise the importance of trademark establishment 
strategies (Chong et al., 2008). 
 
Costs for both patents and regulatory approvals add up to a large amount of money, hence it has a great 
risk connected to the procedure (Chong et al., 2008). This might create a double risk since an invented 
food product might not pass the criteria to be patentable and if patentable and patented it might not pass 
a regulatory approval to be released on the market. This creates negative incentives, both for internal 
and external investors such as venture capitalists and business angels, due to the high uncertainty and 
relatively low expected return on investments. 
 
IPR cost money, both during the application and for maintenance purpose. Metcalfe (2015) created a 
financing model based on different funding sources during the venture creation process. In the model, 
viewed in figure 6 below, ventures can identify in what stage they are and by that tailor the financing 
activities. In general, the funding sources for early start-ups is self-funding and bootstrapping. 
Bootstrapping means that a venture tries to keep the cost low by choosing activities that are not 
expensive and the operational staff have incomes besides the venture Metcalfe (2015). In a validation 
stage, a venture can apply fore governmental funding. During the expansion stage, after the first sales 
have been performed, private venture capitalists can invest capital in the venture.  
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2.2.4 Consumer acceptance  
FFs can only be a successful category of food products if the consumers accept it. During the previous 
decades, the consumer demand of food products has changed considerably, where consumers more and 
more link their habits of food consumption with health (Siró et al., 2008). The increased demand of 
health related foods could partly be explained by increased costs in healthcare, increased desire for 
longer life expectancy and a desire for elderly to improve their life quality at increasing age.  
 
The increased awareness provides great opportunities to develop an almost infinite array of new FF 
concepts. In addition, FFs are considered by consumers to be sold at higher prices, which could result in 
larger profit margins than conventional foods, creating an attractive sector (Schaafsma & Kok, 2005).  
 
A product needs to satisfy four important conditions that are presented as the strategic triangle theory 
(figure 7) by Schaafsma & Kok (2005). The most essential and basic requirements are a good taste and 
an understanding of the concept. Apart from that there must exist an emotional consumer affinity and all 
claims must be true.  
 
 
 
 
 
 
 
 
 
 
 
Other critical factors for the consumer acceptance of FF according to Schaafsma & Kok (2005) are: 
 
• Perception of personal benefit 
• Perceived seriousness of the targeted disease 
• Health consciousness of the consumer 
• Nutrition knowledge 
• Sensory properties 
• Price 
• Technology used (such as genetically modification) 
 
  Taste 
Rational fit Emotional fit 
 Efficiency 
Figure 7: Strategic triangle of consumer 
acceptance (Schaafsma & Kok, 2005). 
Figure 6: Early stage funding sources model (Metcalfe, 2015). 
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A market failure that often occurs connected to consumers and consumption is an information 
asymmetry regarding the social and individual health benefits with consumption of FFs (Malla et al., 
2014). Consumers cannot identify health benefits of FF products without correct and credible labelling 
of health claims. Most often governmental organizations intervene in the labelling to regulate what kind 
of health claims that can be made. Another kind of market failure that occurs in societies, such as 
Sweden, is that the individual is not bearing the costs of health care. It is the publically funded health 
care sector that will face these costs. Moreover, consumer related market failures could lead to 
production of a smaller quantity of FF than is socially desirable (Malla et al., 2014).  
 
Sweden is in the forefront in the development of FF in Europe and the FF sector of the food industry is 
one of the most advanced concerning research and technologies in the world according to Stenberg 
(2010). This development has been possible mainly because the Swedish consumers are highly health-
conscious and interested in health and nutrition. The three dominating areas of FF consumption are 
functional bakery products and snacks, dairy products and functional beverages (Schaafsma & Kok, 
2005). 
 
2.2.5 Quality assurance 
Quality assurance (QA) is a way of preventing mistakes in manufactured products and avoiding 
problems when delivering solutions to customer (Hoyle, 2009). QA is of major importance in the food 
industry to be able to launch a product on the market and it is regulated by the current industry standards 
for each market. Thus, continuous QA of health claims seem absent as an industry standard. Health 
claims are connected to fixed quantities of single substances but the consumers often eat food in 
compositions of several ingredients. Currently, the only QA method available to predict the glycaemic 
response before a product has been consumed is through meal studies with human test subjects. To 
create statistic relevance of the data, numerous of people needs to be subjects through long time. This is 
a costly procedure of several hundred thousand Swedish crowns. Hence, meal studies are unsustainable 
for use at numerous ingredients since the number of possible compositions is almost infinite. Since QA 
is an important and necessary feature when producing foods, sustainable QA methods relating to health 
claim are needed. This creates opportunities for innovation. 
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3. Methodology 
This study will be conducted in a qualitative manner according to Bryman & Bell (2011). This approach 
will give deep insights into the research topic for the reader. The main novelty is the exploratory 
investigation of the venture creation process in the FF sector. Furthermore, previous research has not 
been explaining the venture creation process from a perspective of early stage FF ventures and therefore 
a qualitative observatory study is required for substantial insights in the process. 
 
The result of the qualitative study will be subjective and cannot be assumed to cover the whole 
population of start-up ventures according to (Bryman & Bell, 2011). However, the qualitative research 
approach is preferred in this case over a quantitative approach due to the relative complex research 
questions that requires action research for the deep insight and understanding. 
3.1 Research design 
The chosen research design is insider action research where empirical data will be collected from one 
specific case, aligned with the research topic to give credibility to the study. The reasoning behind the 
design is that the author has insight and accessibility to such a case as well as it allows for continual and 
longitudinal observations and interventions on a rich, descriptive case that are qualified as fitting the 
thesis definition of venture creation connected to FF (Bryman & Bell, 2011). In addition, insider action 
research allows identifying internal insights that a disconnected observer would not be able to capture. 
In the later stage, the collected data will be analysed and connected to relevant theory. Thereafter, 
conclusions will be made answering the research question.  
3.2 Data collection 
The data collection will have emphasis on the general venture creation process in the case study and 
consist of: historically events, notes, experiences and memories from one year of observations. Some 
data also has been collected in collaboration with the founders of the venture by joint investigations, 
conversations, meetings, telephone calls and data sharing. In total approximate 60 interactions were 
made during the data collection period. Mainly, the generated data will be the author’s personal data 
where actions such as meetings with stakeholders, web browsing and workshops were made on a daily 
basis during the one-year data collection. The collected data will be sorted and placed under the four 
categories of venture creation that was described in the theoretical framework: 1) Planning activities, 2) 
Legitimacy establishment, 3) Market activities and 4) Resource transformation. Throughout the findings 
chapter, where the collected data is presented, discussions of the data will be made. 
3.2.1 Research object 
This thesis work will be based on a case study of a start-up venture from Lund University in Sweden 
called ViscoSens. ViscoSens is in an early stage, founded by three researchers in 2011. The idea about a 
venture started already 2005 with an investigation in the need of sensors in the FF sector. Today, the 
operations are rooted in development and commercialization of a physical analysis technique with 
ability to analyse health impacts of food products and assure quality of labelled products over time. 
ViscoSens was chosen as research object based on the criteria that it is an early-stage start-up venture 
operating with FFs. This validates ViscoSens as a research object, significant for this study.  
3.3 Data analysis 
In the analysis chapter, the theoretical framework will be applied to the empirical data of the case 
through exploratory discussions. The discussions will be related to each of the venture creation 
categories and an analytical model will be created connecting the categories. By compiling the 
theoretical and empirical data in this matter, a hypothesis of a FF specific venture creation framework 
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can be created. The analysis will be the basis of the conclusion answering the research questions in the 
conclusion chapter. Later on, recommendations for further research and further actions in this area will 
be suggested.  
3.4 Criticism/potential risks 
When doing insider action based research, there will always be a risk of conflicts when the one 
conducting the research also is involved in the daily operations (Coghlan, 2001). The risk lies in that one 
could make too many assumptions in a biased way, be reluctant to reframe current thinking or even 
distort data when being very close to it.  On the other hand, there are multiple advantages using insider 
action research to extract data from an internal project. It can be attractive from a research point of view 
to look deeper into actions in a project, which is hard to get through external interviews (Coghlan, 
2001). The possibility to look deeper arises when the observer has insights in the social setting and how 
colleagues are reasoning. Therefore, the observer can easily study certain situations, providing richer 
and more valuable data. 
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4. Findings 
In this chapter, the results presented from one year of observations are connected to how the venture 
creation process has proceeded in ViscoSens when forming a FF business case. The findings has been 
compiled and categorized in four categories: Planning activities, legitimacy establishment, market 
activities and resource transformation. In addition, each category has been deconstructed into several 
subheadings.   The chapter starts with background information of basic facts before the investigation 
was initiated.  
4.1 Background information 
The author was given full access to the ViscoSens before the empirical data collection was initiated. The 
access included demonstration of current technology assets, i.e. an analysis technique for quality 
assurance purposes to predict glycaemic effects of bread. Moreover, the access included underlying 
strategic decisions of future proceedings to generate revenues. The main obstacles for ViscoSens had 
been to conceptualize the analysis technique to make it attractive to industry actors as well as ideas of 
how such concept could create revenue streams. In the process of creating an attractive concept, 
ViscoSens needed revenues to finance further operations. This led to a pivot, a divergent path from the 
initial concept, with considerably shorter time to market. The concept included sales of bakery mixes for 
bread containing high quality betaglucans in ratios 4g per 30g available carbohydrates. This ratio is the 
requirement according to the EFSA-approved health claim of betaglucans for low glycaemic response 
claims. This would generate a legitimate business that would be attractive for the small and medium 
sized bakery actors. The new path met issues in sourcing of high quality betaglucans at reasonable 
prices, as well as the fact that a high quantity of betaglucans affects texture and sensory properties in 
bread in a negative way. At the starting point of this thesis work, ViscoSens was turning back to the 
basic concept of an analysis technique and based on that build an attractive and feasible business case 
with long term potential.  
4.2 Planning activities 
4.2.1 Venture inventory 
The first action, before the planning activities started, was to map out all components that belonged to 
the assets of ViscoSens, both technology assets, through a demonstration on a basic level to understand 
the most essential elements of the invention, and knowledge assets. The knowledge assets were 
collected through document sharing and interviews with the founders as well as with ViscoSens 
investors to determine individual visions and how they wanted to conduct further commercialization. 
The map out of knowledge assets followed the “bird-in-hand” principle according to effectuation logic 
by Read et al. (2010). It was considered of major importance to account for every stakeholder’s interest 
and knowledge areas to create maximum value of the venture. The investigation yielded hypotheses of 
concepts and value propositions that potentially could suit customer needs. The strength of ViscoSens 
was determined to be the human capital in the area of food technology and human nutrition. From the 
investigation it seemed reasonable to aim for a concept with grounded roots in the analysis technique but 
still with urge for a relatively fast market launch. 
 
The technology demonstration revealed that the analysis technique was based on two scientific research 
articles published by one of the founders (Östman et al. 2006), (Ekström et al. 2013). The articles 
describe a way to mimic the human digestion system followed by certain analyses with results that could 
be linked to benefits of low glycaemic response through correlations with clinical meal studies. This 
indicated an in vitro method that could replace meal studies in analyses of real time properties in food 
products.  
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4.2.2 First concept: health claims 
From these facts, an initial decision was made that the principles of the existing method was a good 
starting point, though the method needed improvements to work integrated in an industry production 
process as a quality assurance method. Through the process of working with the planning activities, new 
information and data was constantly flowing into the venture, as intended in a creative phase. The 
information consists of external environment factors that need to be considered to make creative plans 
realizable. This was the case when exploring how a health claim could be fitted into the method, which 
is further described in the establishing legitimacy chapter. The generated information eventually created 
entry barriers that forced a decision of a planning pivot.  
4.2.3 Second concept: medical device 
The information above showed that many FF concepts, which have experienced the tough health claim 
regulation, turn towards framing the products as consumable medical devices. The regulatory path for 
medical devices seemed to have certain benefits such as: shorter administration time, less costs and 
higher degree of protection of sensitive information. This is mainly due to a decentralized, national, 
regulation management system. Each national authority are authorized by the EU to approve medical 
devices by themselves compared to a centralized, EU common approval system for health claims. The 
medical device regulation enables health claims based on documentation, which is provided to the 
national authorities. The administration is fast and the claims are not free for other organisations to use. 
This seemed attractive for ViscoSens but the obstacle was to reframe the concept to fit into the medical 
device regulation. Therefore, ViscoSens contacted regulatory consultants with expertise in medical 
devices. The general response was that they liked the idea and saw a great need of such an analysis 
technique but in itself it could not be framed as a medical device since the analyses were made outside 
the body and not inside or in connection to the body. Therefore, it was recommended to aim for a 
validation as a quality assurance method. The analytical data could in that case work as cause-effect 
assurance that could leverage health benefits claims for medical foods. The suggested path was to 
accredit the method as a validated analysis technique of the glycaemic response in products and 
thereafter aim for making it an industry ISO standard for such analyses. These suggestions opened up 
the idea of another path to communicate health benefits for all FF. This was the seed for the second 
planning pivot.  
4.2.4 Third concept: quality-quantity analysis 
New technologies and tools possess the power to change frameworks in the society that have been 
created based on existing technologies at the time when the frameworks were formed. This was believed 
to be the case when EU formed the directives about health claims. No feasible quality assurance 
technologies of health claims were available in 2006 when the health claim directive was introduced, 
and therefore the legislation does not contain such requirements. ViscoSens possesses the ability to 
change the current legislative framework for health claims in foods. By measuring quality-quantity 
parameters of ingredients with already approved health claims, the new technology owned by ViscoSens 
can introduce more accurate health impacting levels. In the case of betaglucans, the quality depends on 
different factors such as the cereal kernel source and the extraction method, the glycaemic effects, in 
turn, and thereby the health effect, highly depends on betaglucan quality. Therefore, instead of basing 
the health claim requirements on betaglucan quantity, it should be based on a measured quality. A 
hypothesis was made that the decision of analysis data acceptance could be administered on a national 
level since it is not included in current European legislation. The new, third, concept included 
communication of measurement data as a leverage of proving health benefits and creating an end 
consumer communication concept that could be used on product packages. The obstacle would be to 
educate consumers about the meaning of the data so they could recognize it as a health benefit. 
4.2.5 Temporary business model and value proposition 
When ViscoSens decided to try the quality-quantity concept with potential customers, a temporary 
business model was created. The framework used was business model canvas by (Osterwalder, 2004). 
The temporary business model can be viewed in appendix 1. The business model still was seen as 
preliminary to be refined or pivoted to a verified model, through interactions with potential customers. 
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A verified business model will serve as leverage towards investors to fund ViscoSens. The most 
essential part of the business model canvas was considered to be the value proposition. The value 
proposition communicates how the assets can be transformed into customer utilities that will create 
value and profit opportunities for the customers. ViscoSens chose to describe the value proposition as a 
short-term profit proposition since it was  “business to business” (B2B). The main focus was set to 
attract new customers in order to create recognition and interest among industry actors. The short-term 
pay-off proposition offered variable costs for the customers instead of investments in assets. The value 
proposition as well as the other categories in the business model canvas can be viewed in appendix 1.  
4.2.6 Timeline and vision 
To realize the business model, ViscoSens created a timeline of important activities, which leads towards 
the stated vision. The vision was a long-term goal that would guide the actions and operations in 
ViscoSens: “Performance of physical analyses of health benefits in all kind of food products, both for 
characterizations in specific ingredients and health impacts in compositions of food products”. The four-
year timeline to work towards this vision can be viewed in appendix 2. 
4.3 Establishing legitimacy 
4.3.1 Regulatory preparation 
Initially, ViscoSens was aware of the hindrance that could occur before market entry due to the 
regulatory approval requirements for the concept. The analysis technique was not a single food product, 
more a technology that enabled food producers with claiming functionality and health benefits for their 
products. Hence, there were problems defining what legal framework that was applicable since the 
conceptual framing did not fit into any framework. The analysis technique could be viewed as a health 
claim enabler or as a method that need a health claim attached to it. The believed key activity was to 
start with the regulatory work as early as possible and execute a plan for quick feedback of how the 
concept could be refined to have an easy passage through the approval process. ViscoSens created 
hypothetical strategies of possibilities to adapt the current health claim regulation into the concept. 
Furthermore, ViscoSens learned through conversations with experts within food regulations that the 
view on the analysis technique actually could be different depending on the rhetorical framing to the 
approving authority. 
4.3.2 Health claims 
While investigating the adaption to health claim regulations, ViscoSens struggled with the high number 
of health claim rejections for products with low glycaemic response due to difficulties to characterize 
the heterogeneous carbohydrate compositions. Furthermore, the dependence of the analysis technique 
for a claim was questioned since the health claim regulation approved to make claims based on specific 
quantity of an approved substance, not based on health effects related to quality. ViscoSens knew 
through initial analyses that there are quality differences in every ingredient, which affects the outcome 
of health benefits. Hence, one option was that glycaemic response health claims can be quality verified 
by ViscoSens analysis technique and thereby independent on certain quantities of ingredient additives. 
Furthermore, this included that EFSA approved the analysis technique as a health claim enabler making 
it possible to claim health benefits for products with low glycaemic response. The analysis technique in 
itself was concluded to have no direct legal boundaries to be used. However, without the ability to make 
associated claims on products, companies would, most certain, not see any value in using the technique. 
The process of receiving a health claim was then studied. The identified obstacles for ViscoSens were; 
the expected administration time of minimum five months until feedback opinion, the high costs for the 
approving process as well as the lobbying effort at the EC to get the analysis technique approved. 
4.3.3 Medical device 
A hypothesis that the analysis technique could receive an approval as a medical device was made since 
it measured an actual health effect independent of product. The criterion was that the product should be 
consumable. Many consumable medical device products have been observed in the market. 
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The regulations seemed easier in the path Medical device, as was described in the planning activities 
chapter. Medical foods are foods that are specially formulated and intended for the dietary management 
of a disease that has distinctive nutritional needs that cannot be met by normal diet alone, and were an 
up and coming category of foods. It was also discovered that more governmental funding was granted to 
medical food projects since they could make an easy connection with solution to specific diseases and 
societal problems. Despite the potentially easier approval, the conclusion had to be made that the 
analysis technique could not be classified as a medical device. Nevertheless, it seemed as an interesting 
category if cooperation could be established with medical food producers, whereas ViscoSens method 
could be used as a quality assurance of health effects. From authorities it is communicated that 
continuous quality assurance is important for validation of health effects in medical devices. Therefore, 
the alternative “medical device” stayed as a component in the business model.  
4.3.4 Quality-quantity analysis 
The concept of making quality-quantity analyses that was described in the planning activity chapter was 
considered minimizing the level of regulatory activities since the initial focus was to work with already 
health claim approved substances. The long-term aim is to develop and create a novel industry ISO 
standard for analyses of glycaemic response. The ISO standard would work as a platform that 
companies could adapt by purchasing equipment and methodologies from ViscoSens. By adapting to the 
ISO standard as a quality assurance system, the companies would be able to launch products with a 
communication concept that guaranteed certain glycaemic response after consumption. Such claim 
could be “The blood glucose levels after consumption will remain x % lower compared to a reference 
product”. The reference product had to be compared to equivalents of a similar reference product such 
as pure glucose or white bread, dependent on the shape of the launched product. To get the method 
recognized and accepted by the industry actors, it must be authorized and accredited by a governmental 
organization. ViscoSens concluded that the Swedish Board for Accreditation and Conformity 
Assessment (SWEDAC) could be such an organization. The next step towards a regulatory approval is 
to initiate communication with regulatory legislators at the National Food Agency in Sweden to confirm 
how ViscoSens can use analysis data in the communication to end consumers.  
4.4 Market activities 
4.4.1 Technology push vs. market pull strategies 
The traditional way of conducting market activities is to focus on development of a product according to 
a hypothetical specification of needs and postpone customer interaction until the transformation of 
assets into products is finished, a so-called technology push strategy. This strategy characterizes a 
venture that prioritizes development over customer interactions and does it as a linear process. It means 
that the customers will not have the possibility to contribute with their inputs to the product 
development. In many cases, the customer demands will never be satisfied.  
The counter strategy of technology push is called market pull. Market pull is a kind of customer 
development strategy where identifying customers and revealing customer demands through various 
Minimum Viable Products (MVP). Market pull strategies had been successful in many start-up settings, 
although most research has been conducted among software start-ups (Blank, 2012). When a case study 
starts, the assets were already initially developed into a working prototype in the founder’s academic 
settings.  
 
Therefore, ViscoSens decided to view their current prototype as the first MVP and focus into a market 
pull strategy based on customer demands. Moreover, ViscoSens wanted to operate within the outlined 
field of expertise in health, nutrition and food technology for maximum utilization of knowledge assets. 
Therefore the spectrum of fully adapting to customer demands was narrowed. This led to a combined 
technology push and market pull strategy where the linear elements consisted of the relative narrow 
spectrum of operations and the iterative elements consisted of revealing customer demand within the 
outlined spectrum. 
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4.4.2 Customer interactions 
The market activities were considered as a formation of the value proposition and it started in the first 
customer interactions. The basic idea of the value proposition was to solve identified problem 
statements. ViscoSens formed and analysed the customer’s problems through continuous conversations 
and meetings in addition to applying the previous knowledge in the field. From there, ViscoSens started 
to form cases that would be long-term beneficial for all parts. As far as the customer interactions have 
proceeded, the results are summarized in four bullet points below.   
 
• The current analysis technique has been partly verified to have potential of great use for the 
customers.  
• The prototype, in its existing shape, could work as a MVP that could fill a purpose as a 
demonstration tool used to show customers the principles of the analysis technique.  
• The prototype could generate analytical data on customer’s products that could be valuable and 
thereby sold, which could generate initial revenues for ViscoSens. This without involvement of 
any health claims when customers sell analytical quality assurance data of their products to other 
businesses. 
• The ability to communicate analytical data to consumers in form of health claims is important to 
build a concept that is creating added value for consumers. Thus, the analysis technique has 
potential to change the regulatory framework for glycaemic response related health claims. 
 
The next major activity will be to identify customers who are willing to pay for the data generated by 
the current analysis technique. The most important conceptual verification will come when a first 
product has been sold to end consumers. That will generate actual feedback that the concept is attracting 
and adds value, both for ViscoSens and its customers. Hence, should the customer or consumer demand 
not be served, ViscoSens is ready to make another pivot since they know that a start-up has to be fast 
moving and flexible. Moreover, another possible reason for a pivot could be if the regulatory strategy is 
not working and there is a need to find a new way to frame the concept to pass the regulatory 
requirements. In addition, financial requirements and time to market are important aspects that also 
could force pivots. 
4.5 Resource transformation 
4.5.1 Product development 
Product development is an important activity for FF based ventures and it will remain so even if, in this 
case, it was considered to be a secondary activity after planning activities, regulatory approvals and 
customer development. Since no operational personnel have been employed in ViscoSens during this 
case study, the product development has been on hold. This was seen among the stakeholders to be a 
preferred status since the considered importance of a formed and customer verified concept before any 
further product development. Sometimes product development also creates boundaries and limitations. 
Therefore, the conceptual planning also has included product development aspects. Some hypotheses 
have been created simultaneously with other activities. Those hypotheses will not be brought up in this 
thesis since they contain sensitive information that has potential of being the basis for a patent 
application. Though, the main focus of product development is expected to be put on improving the 
quality of the analysis technique, making it atomized and cover a wider range of performance 
parameters to generate more precise and reliable data. 
4.5.2 Intellectual Property Rights 
The general response from venture financiers has been that ViscoSens need a patent portfolio. This was 
considered to be essential both for funding purposes and to be protected on the market when the product 
starts selling. ViscoSens perceived this recommendation as vital for success. Therefore, a brief freedom 
to operate (FTO) analysis was performed, which revealed that there was not high intensity of patents in 
similar fields as the analysis technique, analysing health effect in vitro. The initial conclusion made 
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from the analysis indicated that the barriers of being granted a patent was not high and there were no 
hindrance entering the market today. A considered advantage that ViscoSens possesses is that the 
founders are world-class experts in the research field of nutrition, health and food technology and 
thereby are pioneers in the field of measuring health effects in food products. Due to this level of 
expertise within ViscoSens, the probability of other unknown actors patenting similar technologies was 
considered low and thereby the urge of performing a patent application did not seem very high. 
Therefore, the possibilities of keeping the technology a trade secret seems reasonable until funding has 
been received. The issues with trade secrets, that ViscoSens was aware of, is the sensitiveness of 
information about the technology. Thereby, nothing essential of the technology can be published, 
otherwise the novelty could be ruined and there will be no possibilities of receiving a patent. Moreover, 
before the case study was initiated, a patent attorney performed an initial novelty search with positive 
outcomes of possibilities in patenting the invention. To initially protect the assets of ViscoSens, a 
trademark was filed and granted with the name and logotype. Thereby, tangible value can be created in 
the brand valuable for a possible exit. 
4.5.3 Funding 
Funding is always an obstacle for start-up ventures and especially those who are research based with a 
long time of development before being able to enter the market. The most reasonable is to in an initial 
phase apply for governmental grants, which also is called soft funding. The major part of the soft 
funding in Sweden is granted by a governmental organisation called Vinnova, but there are also a 
variety of scholarships from funds that could be applied for. The obstacle is that the competition for the 
soft money grants is huge and the administration time before a decision is long. To only rely on 
governmental funding is risky but if such money is granted, ViscoSens could focus on more important 
things of venture creation than apply for funding with a limited amount of spendable time. ViscoSens 
has identified that they are somewhere between pre-seed and seed phase of the funding cycle by 
Metcalfe (2015) illustrated in figure 6 in the theory section. As could be viewed in the figure, the 
expenses are high and the profit is negative.  
 
A potential model for funding that came to knowledge was to get funded by potential customers. This 
model stemmed from the customer development reasoning. If the customer demand were high enough, 
they would be willing to partly pay for the development cost of the product. In businesses that target 
consumers, a so-called business to consumer (B2C) model, a campaign of crowd funding could be 
created. There early adopters of the product watches a pitch film and decides if they want to donate an 
optional amount of money in return to receive the product before everyone else or just to make it reality. 
When having a business targeting other businesses through a B2B model, the best way of funding is for 
the potential customers to fund the technology development. If funding is received from potential 
customers this is feedback to ViscoSens that the value proposition targets a real customer demand. 
Potential customers often say that they are interested in the project and when a product is finished they 
might also buy it. Moreover, they could even sign a letter of intent saying that they are going to buy the 
product when it is finished, but this is never a binding document, which could lead to failures if relying 
on these documents too much.  
 
It would be a possibility for ViscoSens to seek venture capital (VC) and business angel investments. In 
the current stage, it was considered by ViscoSens to be too early since no sales had been performed. The 
reasoning behind this was that a first sale would raise the valuation of the venture and by that ViscoSens 
could receive more capital for less ownership to the funders.  
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4.6 Summary of the case 
Table 3 below summarizes the essential outcome of the findings that will be brought to the analysis 
chapter. 
 
Table 3: Summary of the result from the venture creation categories. 
Venture creation 
categories 
ViscoSens 
Planning activities Preliminary concept: Communication of measurement data, based on quality-
quantity analysis, as a leverage of proving health benefits and creating an end 
consumer communication concept that could be used on product packages. 
 
Establishing legitimacy Health claims: No quality assurance aspect currently included in the health 
claim regulation. Observed high barriers of receiving a health claim approval 
since the analysis technique did not fit into the framework of health claims. 
 
Medical device: Analysis technique no medical device by itself but with 
cooperation with medical food producers it could work as a health effect 
quality assurance, which was necessary to possess be approved as a medical 
device. 
 
Quality-quantity analysis: Communication of accredited analysis data of 
already approved health claim substances where the quantity of ingredient is 
based on the quality and health effect. The quality assurance technique should 
be accredited as a validated analysis technique and in the end an industry ISO 
standard 
Market activities Market strategy: Combined market pull and technology push strategy since 
the first MVP already was developed and a customer demand is important to 
consider before further product development. 
 
Customer development: The potential customers have partly verified the 
concept and believe that important data can be generated with the current 
analysis technique. The potential customers still emphasise the importance of a 
communication concept of analysis data to consumers to be able to create 
added value. 
 
Resource transformation Product development: Product development is considered as a less important 
activity in the current status of ViscoSens. Though, some hypotheses of 
further product development have been conducted to be able to realize the 
venture vision in a realistic manner. 
 
IPR: Initial FTO and novelty searches have been performed with positive 
outcomes. There are no patents hindering a market entry. A patent will be 
applied for when funding is secured. A trademark has been applied for and 
granted as a sign that ViscoSens is aware of the IPR situation. 
 
Funding: Governmental grants and funding by potential customers will be the 
major source of funding. In the next phase will VC and business angel 
investments be the major source of funding. 
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5. Analysis 
The analysis chapter consist of analyses that connect the theoretical framework with the empirical data 
collection. The emphasis has been on different perspectives of activities when creating a FF business 
case.  
5.1 Analytical framework 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The analytical framework, seen in figure 8 above, has been created to join the theoretical contribution 
with the empirical data collection and put in perspective of how the activities interact in the creation of a 
FF start-up venture. No found theory has previously described a proposed framework for venture 
creation in FF start-ups, which is the reasoning behind an establishment of such a proposal. The 
activities have been divided into internal, external and fusion activities. Fusion activities indicate both 
internal and external activities. 
5.2 Internal activities 
The internal activities are defined by activities that are performed inside the venture and work as a 
scaffold that are necessary in development of a sustainable business.  
5.2.1 Venture 
The figure indicates that the venture creation starts with the formation of venture constellation, as was 
described in the findings as venture inventory. That could consist of a team of founders accompanied 
Venture
Planning activities
Intellectual property 
rights Regulations
Technology 
developm ent and 
ver ificat ion
Custom er 
developm ent and 
cooperat ion 
establishm ents
M arketing and brand 
establishm ents
Figure 8: Illustration of the analytical framework of factors influencing a FF start-up venture. 
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with some kind of assets, technology, knowledge or both. It all starts with an idea of how some assets 
could be transformed into a product or service serving a hypothetical market demand.  
5.2.2 Planning activities 
An idea needs planning to be realized and therefore the idea generation follows by a planning phase, 
which was established both in theory and findings. The planning activities are a general cause for almost 
every venture independent of industry direction and central to perform other operational activities in a 
structured and carefully prepared manner.  
 
The technology assets of ViscoSens differed from the majority of FF concepts, which usually are 
consumable food products with health benefits. Therefore, the planning activities could be seen as more 
flexible than when for instance commercializing a FF ingredient since hardware technology could be 
adjusted to customer demands more easily. Nevertheless, more common FF could focus on specific 
demand of certain health benefits and then develop applications and compositions according to customer 
demand. Therefore, it is a necessary activity in all FF ventures to include customer development as a 
central piece in the planning activities.  
 
ViscoSens chose to focus the planning specifically on concept creation and value proposition generation 
of the business model instead of further product development. It seems like that choice led to the ability 
to take an external approach. The cause of starting with these categories was that they got an opinion 
that this was enough for the planning phase. It is always a utopia to plan all future operations in detail 
followed by that everything turns out as one thought, but the reality tells you otherwise and as an 
entrepreneur one needs to value the limited time there are to distribute. Therefore a typical business plan 
should not be created before some verification or execution has been performed since the risk of being 
forced to make pivot is high and then the whole plan have to be remade. A business plan usually takes a 
couple of months to write compared to a business model that is just a way to structure a business 
hypothesis. Therefore, the creation of a business model seems more reasonable for a better distribution 
of time.  
 
ViscoSens chose to perform a timeline to structure the activities of commercialization. Such document 
could be valuable both as an internal document when deciding to prioritize activities and as a 
presentation document for investors as an illustration of how the plan is going to turn into reality. The 
necessity of a timeline in an early stage can be questioned. According to the author, that depends on the 
internal structure in ViscoSens. If the founders/investors are not involved in the operational activities, as 
in the case of ViscoSens, a timeline is preferred as a decision material. If the entrepreneurs are the 
founders a timeline could possibly wait until a later stage.  
 
The planning activities category is the gateway to all other venture creation activities except the 
technology development and verification since it should be performed according to verified customer 
demand rather than internal ideas.  
5.2.3 Regulations 
To create a legit business, approvals to release a product on the market needs to be obtained. For FF 
businesses it is often connected to regulatory approvals. An entrepreneur needs to know the legal 
barriers to enter the market otherwise a business could fail after huge amount capital and time spending 
on other costly activities.  
 
Regulations could be viewed both as an internal and external activity but the author has chosen to view 
it as an internal activity since it highly depends on framing the concept and intended application of use. 
One must be aware of additional regulations that have not been specifically brought up in this thesis 
such as a classification called novel food. If a food product has not been consumed or consumed in 
intended quantities within EU before 15th of may 1997 it will be considered as a novel food. The 
implication of this regulation is that the FF, more or less, will be viewed as a pharmaceutical agent or 
genetically modified food product and loads of costly toxicology studies during long time have to be 
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performed. In addition, the health claim regulation needs to be performed separately. In theory, these 
regulations in combination are not recommended to perform for start-up ventures since the financial 
assets and necessary experience usually are not settled.  
 
ViscoSens started the venture creation process with a lock-in that FF concepts equal health claims, 
which still is the most common regulatory route. Though, it seem like a good decision to start 
investigate other routes as well. That created a wider spectrum of possibilities to frame the concept. 
Even if the first regulatory investigation will be to introduce a quality assurance parameter of health 
claim and possibilities of communication validated analysis data without involvement of health claims, 
the medical device pathway will still be an optional side-track. If ViscoSens will choose to apply for a 
health claim or performing lobbying work to introduce a novel paragraph in the health claim regulation, 
the venture should consider looking for collaboration partners with preferred financial and knowledge 
assets for this matter.  
 
Some critique that has appeared is that EFSA has problem to separate FF from pharmaceutical products 
where they are applying similar level of safety requirements for FF as for a disease treating 
pharmaceutical agent, i.e. with numerous clinical studies. Moreover, FFs are not disease treating agents; 
they are preventive and proactive agents that reduce the risk of getting a chronic disease. From there it 
could be discussed what kind of framework that is applicable for FF and here opinions differ. EFSA is a 
young organization, created in 2002, and they need time to adapt to the consumer and industry 
requirements. Therefore, it will most likely be introduced changes in the safety requirements to open the 
market of FF further. This because most stakeholders in the FF regulatory arena are agreed that major 
benefits such as societal savings can be achieved due to a better health of the population.  
 
The awareness of regulatory challenges with receiving health claims in addition to the lack of secrecy 
when filing for a health claim has increased the rate of medical device classified FF. The medical device 
directive (EC No. 93/42, 1993) is standardized in different classes with fixed regulatory requirements, 
which makes it easier for companies to adapt and tailor studies to create safety evidence. The medical 
device classification is approved on a national level by notified bodies. This increases the interactions 
and communication between approval institution and companies, which is favourable for everyone due 
to a faster approval process. When filing for a medical device, the documentation and claim will be seen 
as property that will make it hard for potential competitors to benefit from others approvals.     
 
5.2.4 Intellectual Property Rights 
Many advisors consider IPR as assets that are necessary when creating value in a technology based 
venture. That could be discussed from many perspectives. The theory is, in the case of patents necessity 
as IPR, arguing for that it inhibits the innovativeness in the FF sector. The author argue that patents will 
generate more venture capital investments to start-ups and that will in the later run create higher 
incentives and opportunities for entrepreneurs to create new innovations in this field. According to that 
there are limited available property rights when going through health claims, patents seems like the only 
way to claim ownership of an innovation for a longer time. Brands and trademarks are of certain 
importance but it will not inhibit copycat companies from riding on another companies investments in 
R&D generating FF products with health claims as stated in the theory. Trademarks and brand 
establishments are the most common way in the food industry to claim any property and to establish 
customer loyalty. The author argues that branding strategies are preferable for all ventures working with 
FF as a way of connecting with the target group. It will not likely enhance the probability to receive 
investments in the research and development phase, as patents, but it will more likely boost the product 
sales when it reaches the market, which in that case attracts investments for expansion growth. 
 
On the other hand, IPR are expensive to apply for and uphold. Therefore the author argues for the 
necessity of an established IPR strategy. It is of importance to identify the right moment for a patent 
application for maximum protection since a patent protects for approximate 20 years from the filing 
date. Another strategy regarding IPR could be to continuous inventing attributes to the innovation. Then, 
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others cannot block the innovation on the market in addition to that the components of the innovation 
will be kept secret from external actors. 
5.3 External activities 
5.3.1 Customer development and cooperation establishments 
The first and most important external activities are the customer development and cooperation 
establishments. It is a matter of risk factors surrounding a technology based venture. As described 
before, the most fundamental piece of a business is that someone is going to pay for a product/service. 
Therefore, a venture will have a less risky path towards creation of a business when the potential 
customers play a part in the development of the product/service. Cooperation with other players is also 
fundamental for the speed of venture creation since all knowledge and necessary assets might not be a 
part of the venture.  
 
ViscoSens is targeting a so-called blue ocean market (Kim & Mauborgne, 2015). This means that 
ViscoSens is pioneers in creating a new market category in quality assurance of food health effects. A 
blue ocean market has certain pros and cons. The pros are that there are no established actor and thereby 
no competition. If a demand is identified in a blue ocean market, there are endless opportunities. Many 
investors often seek ventures with blue ocean potential due to the opportunities and possibilities to 
create a global business. The cons are that no market structure is established, for instance with 
regulatory affairs. In addition, no prior market demands has been identified since there are no other 
products available and business manage with the existing technology available on the market. This 
seems challenging when entering the customer development phase. ViscoSens need to develop a 
demand from scratch at potential customers. This can take time and most probably only early adopters 
will be interested in what has been offered. The rhetorical preparation before conversations with 
potential customers will be of outcome importance since it cannot be assumed that they will understand 
more than a simple and shallow explanation of the concept. When developing a customer demand an 
emphasis on competitive advantages that are to be created after implementing the product is of 
necessity. The same reasoning goes for cooperation establishments for awakening interest in potential 
collaboration partners.  
 
A decision to exclude customer development and adapt to a pure technology push strategy would seem 
as risky for a FF venture, already overwhelmed with risk factors. Therefore, the author recommends to, 
as much as possible, continue with the market pull strategy through customer development.  
5.3.2 Marketing and brand establishments 
At the same time as customer development is an important factor in the B2B setting of ViscoSens, 
communication with end consumers and external stakeholders is also of importance. As was described 
in the findings, ViscoSens got much input and information through communication with experts in their 
field such as regulatory consultants. They played a great role in the concept formation. At the same time 
it does fulfil a marketing purpose of the new, up and coming, technology that are about to strike the 
market. By talking to any stakeholder, whether it is consultants, potential board members, customers or 
end consumers, it starts to establish the product and to create customers.  
 
A recommendation to ViscoSens is to start initiating contact with end consumers for their input. This 
could be performed by initiating a small scale concepts of baking bread with verified low glycaemic 
response and bring it to consumer fairs or local bakeries and there initiate contact with the target group.  
 
According to theory are external environmental factors such as consumer trends of importance to adapt 
to in FF concepts. To include this in the market strategy could serve as bridging between technology 
push and market pull. An example is the anti-sugar trend, currently present in the society, that if adapted 
will increase the consumer acceptance of a product. According to the strategic triangle of consumer 
acceptance in the theory section does the products sensory properties pay a great importance on the 
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consumers while getting consumer acceptance. Also the design plays a great role, where the 
communication of evidence based health claims is a central piece. These three are all graspable 
translations of the triangle in figure 4 above. The author is arguing for addition of a fourth piece, which 
is knowledge. Consumers are, in the present status of the society, more and more aware of health 
impacts and how food consumption is affecting health, especially in Sweden (Stenberg, 2010). They are 
also desperately embracing new knowledge due to the rise in interest. This hunger for new knowledge 
often creates miscommunication due to communication of hypotheses not based on scientific data. From 
this reasoning, the author argues that trustworthy and understandable knowledge, not only embedded in 
the health claim evidence, communicated to consumers is today additionally required to receive 
consumer acceptance. The new interpretation of consumer acceptance is illustrated in figure 9 below. 
 
 
 
 
 
 
 
 
 
 
 
5.4 Fusion activities 
5.4.1 Technology development and verification 
The resource transformation regarding technology/product development is dependent on the 
customer/consumer demands as well as regulatory requirements. Therefore it is placed as the last 
category in the analytical framework. As a part of the product development process, FF ventures should 
investigate: consumer demand of claims that will be attributes to the product, the regulatory 
requirements regarding research to achieve these claims and how the development could be designed to 
meet these requirements. From this reasoning it seem obvious that the customer demand and regulatory 
requirements set the agenda both for the clinical studies that needs to be performed as well as the 
technology development activities. 
 
To start the construction process of a first MVP as part of the customer development process seems like 
a fortunate strategy since that will give the potential customer a tangible demonstration of what the 
invention have possibilities to perform. Though, this could not be viewed as a development process 
since it needs to be constructed with minimum time consumption. It is a middle step before the real 
technology development starts.  
 
The theory argues for high costs when developing FF products and thereby funding needs to be 
collected before the development is initiated. In ViscoSens, financial assets and human resources are in 
process to be collected. The technology development will eventually lead to an increase in assets and 
thereby the circle in the analytical framework model is closed.  
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Figure 9: Model of consumer acceptance based on the strategic triangle of consumer 
acceptance by (Schaafsma & Kok, 2005). 
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5.4.2 Funding 
The category of funding is not included in the analytical framework since it is a necessity for every start-
up venture to be able to perform the desired activities.  
 
Before the technology development is initiated, most start-ups can manage the operations by self-
funding and bootstrapping. Bootstrapping mean that “every penny counts” in expenses, i.e. no expensive 
operations are performed and every activity that cost money is weighted against the possible outcome. 
Hence, when the technology development is to be initiated, the financial assets need to be collected. The 
theory has a quite negative view on the financial requirement for product development of FF. They also 
have a view that large multinational companies should make the investments in research and 
development (R&D) so the small and medium sized companies could ride on their investments. The 
author would argue that the development costs for start-up ventures are much lower than for a 
multinational company due to fewer resources, including direct and indirect costs, and a flexible 
mentality. In addition, the need for start-up ventures and SMEs are necessary for the innovativeness in 
the industry and therefore should not the development activities only rely on larger multinational 
companies. Therefore, the author proposes a need of change in the food industry. By benchmarking the 
pharmaceutical industry, the suggestion states that larger companies should be better in investing in 
start-up ventures that preferably are based in academia at universities with extensive development 
experience. Hence, start-ups will have the ability to innovate new FF products that could benefit many 
actors, including the large companies with less spending on R&D and higher return on investments. 
 
Generally it will be favourable for start-up ventures operating in the FF sector to stay as long as possible 
as research projects close to universities. This will increase the opportunities to receive governmental 
grants to fund necessary clinical studies and safety assessments to be able to reach the market. Many 
initiatives needs this kind of verification money in an initial phase to reduce risk, add value and reduce 
time to market, which potentially will increase the probability for venture capital in a later stage.  
 
A proposed list of possible financial sources that could help start-up ventures with the financial situation 
are presented in appendix 1. 
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6. Conclusions 
The conclusions from this thesis is that with the basis of the studied venture ViscoSens, the proposed 
procedure of commercializing the analysis technique in the setting of creating a FF venture is as follows 
(also illustrated in figure 10): 
 
1. Business model proposal 
Firstly one should perform a venture/project inventory and look at the current assets, technology and 
knowledge of the venture to see how these could be linked to hypothetical customer needs. When that is 
done the conceptualization/business model proposal process can be initiated. It is important to remember 
that a proposed business model is not fixed and should be remade on a constant basis. 
 
2. Customer development 
A business starts and ends with customers. Therefore, it is of importance to early identify and interact 
with potential customers, according to customer development theory, to get an overview of their needs 
to be able to create an attractive value proposition for them and remake the business model accordingly. 
In that process could also a first MVP be constructed to show how the technology is intended to 
perform. In the case of ViscoSens, as a B2B business, it is preferred to also perform end consumer 
investigations to identify the demand of certain health benefits. 
 
3. Business planning 
The business planning is an activity that shows how the business model is going to be realized and that 
includes e.g. to create an IPR strategy of how to handle the intellectual assets and create a strategy and 
plan for the technology development. The first three activities most likely have to be funded through 
bootstrapping. 
 
4. Asset generation 
When the business planning is performed, a venture is mature to apply for governmental funding and 
scholarships to be able to finance the operations. At the same time, the technology development should 
be initiated dependent on the financial status. When the first draft of a product is developed sales should 
be initiated to get early feedback from customers.  
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Figure 10: Model of the thesis conclusion. 
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7. Recommendations 
7.1 General recommendations 
• The conclusions revealed a model of FF venture creation, which could be interpreted as a linear 
model. A recommendation is to see the model as a non-linear process since it could differ from 
case to case. The model is a proposal of how venture creation in a FF start-up can be performed.  
• A recommendation is also to wait to apply for governmental funding and scholarships until the 
concept is finished and customer interest is partly verified. This will increase the probability of 
receiving the grants since the decision makers usually look for well-defined and realizable 
concepts with already established cooperation agreements between stakeholders and with a well 
thought through plan of how to perform the commercialization.  
• Another recommendation is to not have a lock-in only on external funding possibilities because 
the best way to fund a venture is through sales. External funding is often attached with some sort 
of liabilities and the money cannot be used for every activity that the entrepreneurs want to 
perform. When handling money from sales, they are not bound to anything, which gives 
flexibilities in intended use as well. 
7.2 Next steps for ViscoSens 
 
In the next phase of venture creation, ViscoSens is recommended to increase the customer interactions 
with a larger diversity of potential customers to further reveal the demand. In addition, ViscoSens 
should try to sell the concept and value proposition to the potential customers to make them fund the 
technology development. As was observed in the data collection, ViscoSens has a possibility to sell 
analysis data to customers that can be produced by the MVP.  
 
Furthermore, they need to expand the cooperation network with essential actors, for instance to start 
cooperate with major suppliers. Simultaneously ViscoSens should start engaging in consumer 
investigations to hear the voice of end consumers about the demand for products containing health 
claims with preferable glycaemic response. Concerning that no operational staff are employed at this 
stage, this could be done by hiring students that are doing projects within academia.  
 
Moreover, the funding is still an issue that needs to be accounted for. Governmental grants should be 
applied for to spread the risks if potential customers are not interested in funding the technology 
development. In parallel with the funding collection, the regulatory plan should be executed since this is 
a time consuming process, regardless of regulatory path. 
 
In the next phase after funding and regulatory execution has been initiated, ViscoSens should start the 
process of employ operational staff that can lead the technology development as well as collecting data 
to validate the method. When the technology is under development, ViscoSens should additionally look 
for novelties in the invention that could lead to a patent application. 
 
The last recommendation for ViscoSens is to try to perform the activities according to a decided 
timeline because it will give you trustworthiness towards stakeholders, whether it is the shareholders, 
investors or governmental institutions. 
 
 
 
 
 31 
Bibliography 
Baylor, N. W. Regulatory Approval and Compliances for Biotechnology Products. In Shimasaki, Craig, 
ed. Biotechnology Entrepreneurship: Starting, Managing, and Leading Biotech Companies. Academic 
Press, 2014. 
 
Blank, S., & Dorf, B. (2012). The startup owner's manual. K&S; Ranch. 
 
Brem, A., & Voigt, K. I. (2009). Integration of market pull and technology push in the corporate front 
end and innovation management—Insights from the German software industry. Technovation, 29(5), 
351-367. 
 
Bryman, A., & Bell, E. (2011). Business Research Methods 3e. Oxford university press. 
 
Chong, L. K., Udell, L. J., & Downs, B. W. (2008). Branding, Trademark and Regulatory Approvals in 
Nutraceuticals and Functional Foods. Nutraceutical and Functional Food Regulations in the United 
States and Around the World, 405. 
 
Coghlan, D. (2001). Insider Action Research Projects Implications for Practising Managers. Journal of 
Management Learning, 32(1), 49-60. 
 
Ekström, L. M., Björck, I. M., & Östman, E. M. (2013). On the possibility to affect the course of 
glycaemia, insulinaemia, and perceived hunger/satiety to bread meals in healthy volunteers. Food & 
function, 4(4), 522-529. 
 
Gartner, W. B. (1985). A conceptual framework for describing the phenomenon of new venture 
creation. Academy of management review, 10(4), 696-706. 
 
Herath, D., Cranfield, J., Henson, S., & Sparling, D. (2008). Firm, market, and regulatory factors 
influencing innovation and commercialization in Canada's functional food and nutraceutical 
sector. Agribusiness, 24(2), 207-230. 
 
Hoyle, D. (2009). ISO 9000 Quality Systems Handbook: Using the standards as a framework for 
business improvement. Routledge. 
 
Hårsmar, C. F., Åsheim, N., & Karlsson, T. (2014). A study of the different views of the financial gap 
issues for university spin-offs. Master’s thesis from Chalmers University of Technology and the Faculty 
of Engineering at Lund University. 
 
Kim, W. C., & Mauborgne, R. (2015). Blue Ocean Strategy, Expanded Edition: How to Create 
Uncontested Market Space and Make the Competition Irrelevant. Harvard Business Review Press. 
 
Liao, J. J., & Welsch, H. (2008). Patterns of venture gestation process: Exploring the differences 
between tech and non-tech nascent entrepreneurs. The Journal of High Technology Management 
Research, 19(2), 103-113. 
 
Malla, S., Hobbs, J. E., & Sogah, E. K. (2014). Functional Foods, Health Benefits and Health Claims. 
Athens Journal of Health 1(1), 37-46. 
 
Menrad, K. (2003). Market and marketing of functional food in Europe. Journal of food 
engineering, 56(2), 181-188. 
 
 
 
 32 
Metcalfe, M. (2015). Retrieved Jun 06, 2015 from: 
(http://hoteliyo.com/early-stage-funding-sources/) Early stage funding sources for start-ups. 
 
Osterwalder, A., & Pigneur, Y. (2010). Business model canvas. Self published. Last retrieval May, 5, 
2011. 
 
Read, S., Sarasvathy, S., Dew, N., Wiltbank, R., & Ohlsson, A. V. (2010).Effectual entrepreneurship. 
Taylor & Francis. Chapter 9 pp. 72-82. 
 
Regulation, E. C. (2007). No. 1924/2006 of the European Parliament and of the Council of 20 December 
2006 on nutrition and health claims made on foods.Official Journal of the European Union, 3-18. 
 
Regulation E. C. (1993) No. 93/42 of 14 June 1993 concerning medical devices, Official Journal of the 
European Communities, No L 169/1. 
 
Rothwell, R. (1992). Successful industrial innovation: critical factors for the 1990s. R&D 
Management, 22(3), 221-240. 
 
Schaafsma, G., & Kok, F. (2005). Nutritional aspects of food innovations: a focus on functional 
foods. Innovation in agri-food systems, 207-220. 
 
Siró, I., Kapolna, E., Kapolna, B., & Lugasi, A. (2008). Functional food. Product development, 
marketing and consumer acceptance—A review. Appetite, 51(3), 456-467. 
 
Stenberg, M. (2010). Retrieved Jan 03, 2015 from:  
(http://www.ats-sea.agr.gc.ca/eur/4539-eng.htm) Functional Food sector profile. 
 
Verhagen, H., Vos, E., Francl, S., Heinonen, M., & van Loveren, H. (2010). Status of nutrition and 
health claims in Europe. Archives of biochemistry and biophysics, 501(1), 6-15. 
 
Williams Middleton, K. (2010). Developing Entrepreneurial Behavior. Doctorial Thesis. Printed by 
Chalmers University of Technology. 
 
Östman, E., Rossi, E., Larsson, H., Brighenti, F., & Björck, I. (2006). Glucose and insulin responses in 
healthy men to barley bread with different levels of (1→ 3; 1→ 4)-β-glucans; predictions using fluidity 
measurements of in vitro enzyme digests. Journal of Cereal Science, 43(2), 230-235. 
 
 
 
 33 
Appendices 
Appendix 1 
Business model canvas 
 
 
Figure 2: Business model canvas of ViscoSens 
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Appendix 2 
Timeline 
This is a proposed timeline of important activities for commercialization of the analysis technique for 
the next four years.  
 
 
Figure 3: Four-year timeline of activities for ViscoSens. 
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Appendix 3 
Funding sources 
Table 4: Some funding sources in pre-seed/seed phase. 
Financing sources Explanation 
Vinnova VFT 1 Verification grants from Vinnova on up to 300 thousand SEK. Managed by 
the regional innovation offices/technology transfer offices at the 
universities. 
 
Vinnova VFT 2  
“Vinn-verifiering” 
 
Verification grants to university based projects from Vinnova up to 2 
million SEK to commercialize research results.  
Vinnova Challenge 
driven innovation  
Supporting mainly triple helix innovation constellations where academia, 
industry and governmental organizations should, preferably, be involved. 
This is a three-stage process where the grant in the initial phase is 500 
thousand SEK. A requirement is though co-financing from the 
constellation. 
 
EU project funds 
(Horizon 2020) 
 
Horizon 2020 is a large EU fund. This is applicable for ventures 
cooperating in cross-national constellations. 
Scholarship funds There are many scholarships available, especially for innovations targeting 
societal problems such as proactive foods against chronic diseases. To get 
a tailored list, a recommendation is to make a scholarship search from 
stipendier.se. 
 
Almi innovation grant Almi is handling a grant for high technology innovations and a venture can 
be granted from 25 000 – 50 000 SEK. 
 
Loans It is not preferred in an early stage to apply for bank loans. A 
recommendation is to look at the local innovation system where regional 
loans with good terms are granted to ventures. Almi also has such a loan. 
 
 
These financing sources could be a kick-start for a venture but there are numerous other organisations 
for granting soft money than are mentioned here. 
 
Table 5: Financing sources in expansion phase 
Financing sources Explanation 
Venture capital 
investment rounds 
 
Venture capital financing often targets ventures in an expansion phase with 
already established sales. Since they are investing private money, they value 
low risk with the venture strongly. When receiving venture capital financing, 
a venture should expect to give away a large piece of the venture. 
 
Business angels Business angel investments are private investments from wealthy persons. 
These investments are personal and enables through networks and platforms 
such as the Connect network and angellist.co. 
 
Crowd funding Some known crowd funding platforms are kickstarter.com, indiegogo.com 
and fundedbyme.com. 
 
 
